# ZEST (NCT04915755)

> Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04915755
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Neoplasms, Breast
- Interventions: Niraparib; Placebo
- Enrollment: 40
- Primary outcome: Number of Participants With Treatment Emergent Adverse Event (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
- Primary outcome: Number of Participants With TEAEs Leading to Death
- Primary outcome: Number of Participants With TEAEs Leading to Dose Modifications and Discontinuation of Study Treatment
- Primary outcome: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
- Primary outcome: Number of Participants With Worst-Case Post-Baseline (WCPB) Hematology Results Relative to Baseline
- Primary outcome: Number of Participants With Worst-Case Post-Baseline (WCPB) Clinical Chemistry Results Relative to Baseline
- Primary outcome: Number of Participants With Worst-Case Post-Baseline (WCPB) Vital Signs Results Relative to Baseline
- Primary outcome: Number of Participants With Use of Concomitant Medications

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 11
- X threads: 10
- Podcasts: 6
- Bluesky threads: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=zest-nct04915755

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04915755", "email": "<work email>"}; the inbox owner confirms by the emailed link.